NeuroPace(NPCE) - 2025 Q3 - Quarterly Results

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance Reported record quarterly revenue of $27.4 million in Q3 2025 representing 30% growth Increased full-year 2025 revenue guidance to between $97 million and $98 million and gross margin guidance to between 76% and 77% Remains on track to submit NAUTILUS PMA Supplement to FDA for IGE indication expansion by year-end 2025 Mountain View, Calif. – November 4, 2025 – NeuroPace, Inc. (Nasdaq: NPCE), a medical device company f ...